Comparative Pharmacology
Head-to-head clinical analysis: TAPAZOLE versus THYROSHIELD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAPAZOLE versus THYROSHIELD.
TAPAZOLE vs THYROSHIELD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones (T3 and T4) and reducing iodine organification and coupling of iodotyrosines.
Thyroshield (potassium iodide) acts by supplying excess iodide, which inhibits thyroid hormone synthesis via the Wolff-Chaikoff effect, blocks thyroidal iodide uptake, and reduces thyroid vascularity. It also protects the thyroid from radioactive iodine uptake by saturating iodine transport and organification mechanisms.
15-40 mg per day orally in 3 divided doses; maintenance: 5-15 mg per day orally once daily.
Intravenous: Loading dose 200 mg, then 50 mg every 6 hours; or continuous infusion: 200 mg bolus then 800 mg over 24 hours. Oral: 50 mg every 6 hours.
None Documented
None Documented
3-6 hours; clinically, effects persist longer due to intrathyroidal accumulation.
Terminal elimination half-life is 12-24 hours; clinical effect persists 24-36 hours after single dose.
Primarily renal, approximately 65% excreted in urine as metabolites and unchanged drug; <10% eliminated in feces via biliary excretion.
Primarily renal (90-95% unchanged), minor biliary/fecal (5-10%).
Category C
Category C
Antithyroid Agent
Antithyroid Agent